• Have a question?
    Open from 8am to 7pm Monday to Friday    Call customer services
    0345 54 32 600


| Print

Eli Lilly & Co (LLY)

Common Stock
Sell: $1,437.00|Buy: $1,440.00|Change: 16.22 (1.14%)

Open 

$1,429.91

Previous close 

$1,427.28

Trade high 

$1,449.64

Volume 

2,084,332

Year high 

$1,460.00

Year low 

$850.51

Dividend yield 

0.48%

Market capitalisation 

$1.29 tn

P/E ratio 

46.85

ISIN 

US5324571083

This share can be held in a Dealing accountStocks and shares ISALifetime ISAJISASIPP

Share price

Dividends

PreviousLatest
Record date14/08/202613/11/2026
Ex-dividend date14/08/202613/11/2026
Payment date10/09/202610/12/2026
Amount$1.73$1.73

Performance 13/11/2026

1D | 1M | 3M | 1Y | 3Y ann | 5Y ann | 10Y ann

Total return (%)
Eli Lilly & Co+ 1.26
More...

Company profile

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.

Sector 

Healthcare

AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.

© Copyright 2026 AJ Bell. All rights reserved.